Prognostic relevance of secondary actionable fusions in MLH1-deficient dMMR/MSI-H gastrointestinal tumors treated with pembrolizumab
ESMO Gastrointestinal Oncology
· Elsevier
The publisher did not provide an abstract — full text is available via the link below.
Read at publisher →
Citation
Prognostic relevance of secondary actionable fusions in MLH1-deficient dMMR/MSI-H gastrointestinal tumors treated with pembrolizumab. // ESMO Gastrointestinal Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2949819826001111?dgcid=rss_sd_all
Prognostic relevance of secondary actionable fusions in MLH1-deficient dMMR/MSI-H gastrointestinal tumors treated with pembrolizumab. ESMO Gastrointestinal Oncology. https://www.sciencedirect.com/science/article/pii/S2949819826001111?dgcid=rss_sd_all
“Prognostic relevance of secondary actionable fusions in MLH1-deficient dMMR/MSI-H gastrointestinal tumors treated with pembrolizumab.” ESMO Gastrointestinal Oncology.
@article{article44730,
title = {Prognostic relevance of secondary actionable fusions in MLH1-deficient dMMR/MSI-H gastrointestinal tumors treated with pembrolizumab},
journal = {ESMO Gastrointestinal Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2949819826001111?dgcid=rss_sd_all}
}